The pharmaceutical industry relies heavily on its supply chain, but this chain can also have a significant environmental impact due to common factors like high emissions or packaging waste.
Bristol Myers Squibb is yet another example of a Big Pharma company pledging a multibillion dollar investment in the U.S. as the Trump administration tries to woo drugmakers to boost their domestic ...
Pharmaceutical Intermediates Market OverviewThe global pharmaceutical intermediates market is witnessing steady expansion as pharmaceutical manufacturing scales worldwide. Valued at approximately USD ...
This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility ...
[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity at ...
In this interview, Charles Chase, PhD, the VP and Technical Business Development at Asymchem, a technology-focused pharmaceutical manufacturing company, discusses the significant impact of RNA ...
BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: ...
The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a complex ...
Process development is the exercise of creating new and improved manufacturing methods, optimizing them in terms of time and financial efficiency while maintaining regulatory compliance and product ...
What is Real-Time Release Testing? Real-Time Release Testing (RTRT) is an advanced approach to biopharmaceutical manufacturing quality control that improves upon current systems. RTRT is defined as ...
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S. U.S.
Pharmaceutical Technology on MSN
Trump administration ties pricing deals with another nine pharma companies
With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback